Luminex

History

2021: DiaSorin bought Luminex for $1.8 billion

In early April 2021, the Italian manufacturer of equipment for medical laboratories DiaSorin announced the acquisition of American competitor Luminex for $1.8 billion. The deal is expected to close in the third quarter of 2021 if approved by Luminex shareholders.

Headquartered in Austin, Texas, Luminex is developing diagnostic testing products, including platforms based on multiplexing technology. Among other things, the company developed tests for COVID-19, which in 2020 received permission from US regulators for emergency use.

DiaSorin acquired Luminex for $1.8 billion

DiaSorin executives said in a press release that the acquisition will help expand the company's molecular diagnostics capabilities and at the same time strengthen its market position in accordance with the strategic priorities of the DiaSorin. The acquisition will provide DiaSorin with access to Luminex multiplexing technology, as well as Luminex offers in the biomedical industry. The combined company's total revenue in 2021 is expected to be approximately $1.5 billion.

DiaSorin CEO Carlo Rosa notes that the deal will open up unique opportunities for the combined companies for growth and development, complement the portfolio of services and solutions provided by DiaSorin, and also allow the Italian company to prove itself in the US market.

Together, DiaSorin and Luminex will provide unique opportunities for laboratories, researchers, clinicians and patients around the world. By combining our extensive knowledge in the field of immunodiagnostics and molecular diagnostics with Luminex's outstanding experience in the development of multiplexing technologies, DiaSorin and Luminex employees will be able to open many doors, "he added.[1]

Notes